Cancer Prevention Research CM8 AM No Deadline
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Prevention Research 2, 695, August 1, 2009. Published Online First July 28, 2009;
doi: 10.1158/1940-6207.CAPR-09-0142
© 2009 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Related Article
Right arrow All Versions of this Article:
1940-6207.CAPR-09-0142v1
2/8/695    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carbone, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carbone, D. P.
Related Collections
Right arrow Perspective
Right arrow Oncogenesis: Biomarkers
Right arrow Risk Assessment: Biomarkers
Right arrowKey Article

Perspectives

Profiles in Variation: Lung Carcinogenesis

David P. Carbone

Author's Affiliation: Vanderbilt-Ingram Cancer Center, Departments of Medicine, Cancer Biology, and Cell Biology, Vanderbilt University, Nashville, Tennessee

Requests for reprints: David P. Carbone, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University, 685 Preston Research Building, 2220 Pierce Avenue, Nashville, TN 37232. Phone: 615-936-1279; Fax: 615-936-3322; E-mail: david.carbone{at}vanderbilt.edu.

This perspective on Kadara et al. (beginning on p. 702 in this issue of the journal) examines the critical development of genomic and proteomic signatures of lung cancer risk, prognosis, and sensitivity to chemoprevention or chemotherapy. The novel work of Kadara et al. represents the first demonstration that a molecular signature developed in a premalignancy model (in this case, cultured normal human bronchial epithelial cells and increasingly transformed derivative cells) is clinically relevant to invasive lung cancer.


Key Article

Identification of Gene Signatures and Molecular Markers for Human Lung Cancer Prognosis using an In vitro Lung Carcinogenesis System
Humam Kadara, Ludovic Lacroix, Carmen Behrens, Luisa Solis, Xuemin Gu, J. Jack Lee, Eiji Tahara, Dafna Lotan, Waun Ki Hong, Ignacio I. Wistuba, and Reuben Lotan
Cancer Prevention Research 2009 2: 702-711. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.